Feb 23 (Reuters) - Resverlogix Corp RVX.TO :
* Resverlogix - study to evaluate if treatment with apabetalone with standard of care decreases alkaline phosphatase in comparison to placebo and soc
* Resverlogix reports positive FDA type B meeting on design issues relating to a proposed phase 2A kidney dialysis trial
* Resverlogix Corp - in light of guidance received from FDA, phase 2A study design will be separated in two parts
* Resverlogix Corp - part a of study will involve a single-dose pharmacokinetic (PK) study in eight patients receiving hemodialysis
* Resverlogix Corp - PK results from part a will influence dose selection for part B study
* Resverlogix Corp - part B study will be a double-blind, randomized, placebo-controlled, sequential cross-over study with apabetalone
* Resverlogix Corp - intends to file an official investigative new drug (IND) application and proceed with planned phase 2A clinical trial in 2017 Source text for Eikon: ID:nCNWLcGy9a Further company coverage: RVX.TO